The therapeutic potential of psychedelics: the European regulatory perspective
The Lancet February 11, 2023 Florence Butlen‐ducuing, Drummond E-Wen Mcculloch, Marion Haberkamp et al. 28 citations
No Summary
Florence Butlen‐ducuing
Université de Versailles Saint-Quentin-en-Yvelines
3 papers in the library · 45 citations · publishing 2023-2025
Papers
Psilocybin as Transformative Fast‐Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms
Fundamental and Clinical Pharmacology July 16, 2025 Makiath Adebo, Marie Laure Bonnet, Ons Laouej et al. 10 citations
Psilocybin, a serotonergic psychedelic, is being reexamined for treating depression resistant to conventional antidepressants. Recent clinical trials suggest therapeutic potential, though its mechanisms remain unclear. Psilocybin's active metabolite, psilocin, primarily activates serotonin 5-HT2A receptors, which mediate its psychedelic effects, but its role in antidepressant effects is debated. Preclinical work explores neurotransmitter systems, neuroplasticity, and neural circuits involved. Understanding these mechanisms is crucial for validating psilocybin's use alongside SSRIs/SNRIs in mood disorders, especially as depression is projected to become the leading cause of disability by 2030.
Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
European Psychiatry January 1, 2025 Marianne Destoop, Pavel Mohr, Florence Butlen‐ducuing et al. 7 citations
The European Psychiatric Association (EPA) acknowledges the therapeutic potential of psychedelic substances for mental disorders, such as psilocybin for depression, which are nearing regulatory approval in the US and Europe. This policy paper highlights both the benefits and challenges of psychedelic treatments, emphasizing the importance of psychosocial components and ethical, professional aspects for real-world implementation. Four recommendations are formulated to guide further research and clinical integration, aiming for safe, ethical, and equitable access for all patients who may benefit.